Evidence map›Paper›PMID 32194260›Full record

ArticleActa biomaterialia2020

Tumor necrosis factor primes and metal particles activate the NLRP3 inflammasome in human primary macrophages.

Eemeli Jämsen, Jukka Pajarinen, Vesa-Petteri Kouri, Antti Rahikkala, Stuart B Goodman, Mikko Manninen, Dan C Nordström, Kari K Eklund, Katariina Nurmi

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 51 citations in OpenAlex.

  1. Biologic immunomodulators and spinal fusion: evidence, mechanisms, and perioperative considerations.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. In vivo assessment of TiOAnalytical and bioanalytical chemistry · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Glaucoma and microglia-induced neuroinflammation.Frontiers in ophthalmology · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Roles of osteoclasts in alveolar bone remodeling.Genesis (New York, N.Y. : 2000) · 2022
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Eemeli JämsenDepartment of Medicine, Clinicum, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; ORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland. Electronic address: eemeli.jamsen@helsinki.fi.
Jukka PajarinenDepartment of Medicine, Clinicum, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; ORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland.
Vesa-Petteri KouriDepartment of Medicine, Clinicum, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; ORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland.
Antti RahikkalaDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, Viikinkaari 5 E, P.O. Box 56, FI-00014 University of Helsinki, Helsinki, Finland.
Stuart B GoodmanOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5341, United States; Department of Bioengineering, Stanford University, 300 Pasteur Drive, Stanford, CA 94305-5341, United States.
Mikko ManninenORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland.
Dan C NordströmDepartment of Medicine, Clinicum, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; ORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland; Internal Medicine and Rehabilitation, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland.
Kari K EklundDepartment of Medicine, Clinicum, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; ORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland; Rheumatology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland.
Katariina NurmiDepartment of Medicine, Clinicum, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland; ORTON Orthopaedic Hospital of the Orton Foundation, Tenholantie 10, 00280 Helsinki, Finland.
University of Helsinki · FIInvalidisäätiö · FIOrthopaedic Research Laboratories · US

Funding

Wear Particle Disease and NF-kappa B SignalingR01AR063717 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2012 to 2021
$3.5M
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the HipR01AR072613 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B, YANG, YUNZHI · 2018 to 2022
$2.2M
Customized MSCs to Enhance Healing of Bone DefectsR01AR073145 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2018 to 2021
$1.4M
NIAMS NIH HHS R01 AR063717NIAMS NIH HHS R01 AR072613NIAMS NIH HHS R01 AR073145
6 · The paper itself

Abstract

Aseptic loosening of total joint replacements is driven by a macrophage-mediated inflammatory reaction to implant-derived wear particles. Phagocytosis of implant debris has been suggested to activate the NLRP3 inflammasome leading to secretion of interleukin (IL)-1β. However, factors and molecular mechanisms driving the particle-induced inflammasome activation are yet to be fully elucidated. In this study, we investigated the inflammasome response of human primary macrophages to titanium, chromium, and molybdenum particles in vitro. We observed that particles alone were not sufficient to induce IL-1β secretion, but an additional priming signal-such as bacterial lipopolysaccharide (LPS)-was required to license the inflammasome activation. By using specific inhibitors against the inflammasome signaling pathway, we demonstrate that the particle-induced IL-1β secretion depended upon activation of the NLRP3 inflammasome. We further hypothesized that tumor necrosis factor (TNF) could substitute for LPS as a priming signal, and found that particle stimulation together with preceding TNF treatment resulted in inflammasome-dependent IL-1β production as well. Our results show that the NLRP3 inflammasome mediates wear particle responses in human primary macrophages, and its activation does not necessarily require the presence of bacterial components, but can be induced under aseptic conditions by TNF priming. STATEMENT OF SIGNIFICANCE: This study was conducted to elucidate the molecular mechanisms of metal particle-induced IL-1β secretion in human primary macrophages. Production of this pro-inflammatory mediator from wear particle-activated macrophages has been associated with increased bone loss around total joint replacements-a condition eventually requiring revision surgery. Our results confirm that together with a co-stimulatory priming signal, particles of common implant metals elicit macrophage-mediated IL-1β secretion through activation of the NLRP3 inflammasome pathway. We also present a concept of TNF priming in this context, demonstrating that the particle-related IL-1β secretion can take place in a truly sterile environment. Thus, inhibition of inflammasome signaling appears a means to prevent wear particle-induced inflammation and development of peri‑prosthetic osteolysis.

Indexed as

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinHumansInterleukin-1betaMacrophagesPhagocytosisTumor Necrosis Factor-alphaInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinTumor Necrosis Factor-alphaIL-1βInflammasomeMacrophageTNFWear particle

Identifiers

PMID32194260
PMCPMC7729209
OpenAlexW3012422748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.